Resistance to cancer treatment can arise from tumor evolution resulting in development of fusions, mutations, or amplifications and alternative, by-pass signaling pathways driven by other tyrosine kinases including other receptor tyrosine kinases (RTK)33,34. The gene discussed is NTRK1; the disease is neoplasm.